|
|
|
|
|
Becton Dickinson And Company (BDX) |
|
|
|
| |
Becton Dickinson's Yearly Operating Income Growth 5 Years |
| |
|
Select the Comparisons :
|
|
Select the Ratio:
|
Annual Operating Income Annual Growth Rates Y/Y▼
|
Annual Operating Income Annual Growth Rates Y/Y▼
|
BDX Annual Operating Income Growth |
2023
|
2022
|
2021
|
2020
|
2019
|
| Y / Y Annual Operating Income Change |
-7.49 % |
-18.47 % |
88.61 % |
-15.68 % |
17.57 % |
| Annual Operating Income (in millions $) |
$2,111.00 |
$2,282.00 |
$2,799.00 |
$1,484.00 |
$1,760.00 |
| Annual Operating Income Growth
Comment |
Becton Dickinson And Company experienced detoriation of Annual Operating Income for the fiscal year ended 2023 by -7.49% to $ 2,111.00 millions, compare to $ 2,282.00 in Annual Operating Income reported in the previous year. Becton Dickinson's Operating Income decline slowed form -18.47 % contraction in the fiscal year 2022.
Becton Dickinson Annual Income Statement
|
|
You need to upgrade your Flash Player
|
| Companies with similar 2023 Annual Operating Income within Healthcare Sector | Y/Y Operating Income Growth % | 2023 Annual Operating Income | | Pfizer Inc |  -98.84 % | $ 416.000 millions | | Abbvie inc | -29.59 % | $ 12,757.000 millions | | Sanofi | -26.10 % | $ 8,820.000 millions | | Amgen Inc | -17.45 % | $ 7,897.000 millions | | Moderna Inc | | | |
